Trial Profile
A randomized, open-label phase 2 study of 2 regimens, gemcitabine plus enzastaurin and single-agent gemcitabine, in patients with locally advanced or metastatic pancreatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzastaurin (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Eli Lilly and Company
- 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Aug 2007 Status changed from recruiting to in progress.
- 31 Mar 2006 New trial record.